Literature DB >> 32770170

Author Correction: Temporal dynamics in viral shedding and transmissibility of COVID-19.

Xi He1, Eric H Y Lau2, Peng Wu3, Xilong Deng1, Jian Wang1, Xinxin Hao3, Yiu Chung Lau3, Jessica Y Wong3, Yujuan Guan1, Xinghua Tan1, Xiaoneng Mo1, Yanqing Chen1, Baolin Liao1, Weilie Chen1, Fengyu Hu1, Qing Zhang1, Mingqiu Zhong1, Yanrong Wu1, Lingzhai Zhao1, Fuchun Zhang1, Benjamin J Cowling3, Fang Li1, Gabriel M Leung3.   

Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Entities:  

Year:  2020        PMID: 32770170      PMCID: PMC7413015          DOI: 10.1038/s41591-020-1016-z

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


Correction to: Nature Medicine 10.1038/s41591-020-0869-5, published online 15 April 2020. Peter Ashcroft, Sebastian Bonhoeffer and colleagues at ETH Zurich very helpfully alerted us to a syntactical error in our original code, specifically that the likelihood as we had originally specified gave rise to zero probability for two transmission pairs with the most negative serial intervals. Following their lead, we also applied a normalization factor in the likelihood to account for the uncertainty in the symptom-onset dates of the index cases. However, assuming a uniform distribution, the likelihood would differ only by a multiplicative constant and would give the same estimates. We used the bootstrap method to estimate the 95% confidence intervals (CIs). Thus, we re-estimated the infectiousness profile (Fig. 1c; original and corrected versions provided here) and found that the proportion of presymptomatic transmission was 44% (95% CI, 30–57%) (unchanged from the original point estimate of 44%), whereas infectiousness started at 12.3 days (95% CI, 5.9–17 days) (versus 2.3 days in the original text) before symptom onset and peaked at onset (95% CI, –0.9–0.9 days) (versus –0.7 days in the original text). In the revised sensitivity analysis assuming start of infectiousness at days 5, 8 and 11 prior to symptom onset, we estimated that the proportion of presymptomatic transmission was 37–48% (versus 46–55% in the original text) (Extended Data Fig. 1; original and corrected versions provided here).
Fig. 1c

Original and corrected.

Extended Data Fig. 1

Original and corrected.

Fig. 1c shows that infectiousness started to rise substantially only 5–6 days before symptom onset, around the average time of infection, assuming an incubation period of about 6 days (J.A. Backer, D. Klinkenberg & J. Wallinga, Eurosurveillance 25, 10–15; 2020). We further observed that only <0.1% of transmission would occur before 7 days, 1% of transmission would occur before 5 days and 9% of transmission would occur before 3 days prior to symptom onset. Therefore, from a contact-tracing viewpoint, it may be adequate to enquire about close contacts up to 3 days before the index first shows symptoms. Thus, our conclusions about the proportion of presymptomatic spread and time window of interest for contact tracing remain unchanged with the re-estimated infectiousness profile. Therefore, in the version of this article initially published, the 95% CI in parentheses in the third sentence of the abstract and the original third sentence of the sixth paragraph in the main body of the text (25–69%) was incorrect. The correct CI is 30–57%. The time frames (and 95% CI values) in the second sentence of that sixth paragraph (“started from 2.3 days (95% CI, 0.8–3.0 days) before symptom onset and peaked at 0.7 days (95% CI, −0.2–2.0 days) before symptom onset”) were incorrect. The correct time frames (and CI values) are “started from 12.3 days (95% CI, 5.9–17.0 days) before symptom onset and peaked at symptom onset (95% CI, –0.9–0.9 days).” The following sentence (from the text above) is now included after that second sentence: “We further observed that only <0.1% of transmission would occur before 7 days, 1% of transmission would occur before 5 days and 9% of transmission would occur before 3 days prior to symptom onset.” The values in the seventh paragraph of the main body of the text (“from 1 to 7 days”; “0–2 days before symptom onset”; and “46% to 55%”) were incorrect. The correct values are “from 5, 8 and 11 days”; “2 days before to 1 day after symptom onset”; and “37% to 48%” (respectively). The time frame in the first sentence of the tenth paragraph of the main body of the text (“2 to 3 days”) was incorrect. The correct time frame is “5 to 6 days.” The following text is now added to the beginning of the fourth paragraph of the ‘Statistical analysis’ subsection of the Methods section: “A normalization factor can be added to account for the uncertainty in the symptom onset dates of the index cases. Assuming a uniform distribution, the likelihood would only differ by a multiplicative constant and give the same estimates.” Also, the time frame in the final sentence of that paragraph (“from day 1 to 7”) was incorrect. The correct time frame is “from days 5, 8 and 11.” Finally, Fig. 1c and Extended Data Fig. 1 have been replaced accordingly, and the legend to Extended Data Fig. 1 (“to start from 1 days (top left) to 7 days (bottom right) before symptom onset”) is now rephrased (“to start from 5 days (top), 8 days (middle) and 11 days (bottom) before symptom onset”) to match the revised figure. The errors have been corrected in the HTML and PDF versions of the article. The original code has also been replaced with updated code in Supplementary Software 1. Original and corrected. Original and corrected.
  34 in total

1.  A COVID-19 infection incidentally detected during hyperbaric oxygen treatment and preventive measures for COVID-19 transmission in a multiplace hyperbaric chamber.

Authors:  Abdurrahman E Demir; Savas Ilbasmis; Akin S Toklu
Journal:  Diving Hyperb Med       Date:  2022-03-31       Impact factor: 1.228

2.  Estimated Transmission Outcomes and Costs of SARS-CoV-2 Diagnostic Testing, Screening, and Surveillance Strategies Among a Simulated Population of Primary School Students.

Authors:  Alyssa Bilinski; Andrea Ciaranello; Meagan C Fitzpatrick; John Giardina; Maunank Shah; Joshua A Salomon; Emily A Kendall
Journal:  JAMA Pediatr       Date:  2022-07-01       Impact factor: 26.796

Review 3.  Science's Response to CoVID-19.

Authors:  Marcus J C Long; Yimon Aye
Journal:  ChemMedChem       Date:  2021-06-22       Impact factor: 3.540

4.  Modeling the Transmission of COVID-19: Impact of Mitigation Strategies in Prekindergarten-Grade 12 Public Schools, United States, 2021.

Authors:  Gabrielle F Miller; Bradford Greening; Ketra L Rice; Aziza Arifkhanova; Martin I Meltzer; Fátima Coronado
Journal:  J Public Health Manag Pract       Date:  2022 Jan-Feb 01

5.  Viral fibrotic scoring and drug screen based on MAPK activity uncovers EGFR as a key regulator of COVID-19 fibrosis.

Authors:  Elmira R Vagapova; Timofey D Lebedev; Vladimir S Prassolov
Journal:  Sci Rep       Date:  2021-05-27       Impact factor: 4.379

6.  Absent immune response to SARS-CoV-2 in a 3-month recurrence of coronavirus disease 2019 (COVID-19) case.

Authors:  Guosheng Gao; Zhe Zhu; Lingyan Fan; Shuyuan Ye; Zuoan Huang; Qiaoyun Shi; Yedan Sun; Qifa Song
Journal:  Infection       Date:  2020-07-28       Impact factor: 7.455

7.  Simulation of the COVID-19 epidemic on the social network of Slovenia: Estimating the intrinsic forecast uncertainty.

Authors:  Žiga Zaplotnik; Aleksandar Gavrić; Luka Medic
Journal:  PLoS One       Date:  2020-08-27       Impact factor: 3.240

8.  Clinical, immunological and virological characterization of COVID-19 patients that test re-positive for SARS-CoV-2 by RT-PCR.

Authors:  Jing Lu; Jinju Peng; Qianling Xiong; Zhe Liu; Huifang Lin; Xiaohua Tan; Min Kang; Runyu Yuan; Lilian Zeng; Pingping Zhou; Chumin Liang; Lina Yi; Louis du Plessis; Tie Song; Wenjun Ma; Jiufeng Sun; Oliver G Pybus; Changwen Ke
Journal:  EBioMedicine       Date:  2020-08-24       Impact factor: 8.143

Review 9.  Asymptomatic carriage and transmission of SARS-CoV-2: What do we know?

Authors:  Susan Lee; Paula Meyler; Michelle Mozel; Tonia Tauh; Richard Merchant
Journal:  Can J Anaesth       Date:  2020-06-02       Impact factor: 6.713

10.  Comparison of four commercial SARS-CoV-2 IgG immuno-assays in RT-PCR negative patients with suspect CT findings.

Authors:  Jens T Van Praet; Ann-Sofie Coene; Kris Van De Moortele; Patrick Descheemaeker; Marijke Reynders
Journal:  Infection       Date:  2020-09-10       Impact factor: 7.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.